PATENT CLAIM ANALYSIS

Application Number: 15878644
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "139100"]

Abstract:
Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

Claim (Index 57):
The method according to  claim 48 , wherein the antibody is any of the following (1) to (26):\n (1) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO: 3 as CDR1, the amino acid sequence represented by SEQ ID NO: 4 as CDR2, and the amino acid sequence represented by SEQ ID NO: 5 as CDR3; (2) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO: 6 as CDR1, the amino acid sequence represented by SEQ ID NO: 7 as CDR2, and the amino acid sequence represented by SEQ ID NO: 8 as CDR3; (3) an antibody comprising the H chain described in (1) and the L chain described in (2); (4) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO: 9 as CDR1, the amino acid sequence represented by SEQ ID NO: 10 as CDR2, and the amino acid sequence represented by SEQ ID NO: 11 as CDR3; (5) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO: 12 as CDR1, the amino acid sequence represented by SEQ ID NO: 13 as CDR2, and the amino acid sequence represented by SEQ ID NO: 14 as CDR3; (6) an antibody comprising the H chain described in (4) and the L chain described in (5); (7) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO: 15 as CDR1, the amino acid sequence represented by SEQ ID NO: 16 as CDR2, and the amino acid sequence represented by SEQ ID NO: 17 as CDR3; (8) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO: 18 as CDR1, the amino acid sequence represented by SEQ ID NO: 19 as CDR2, and the amino acid sequence represented by SEQ ID NO: 20 as CDR3; (9) an antibody comprising the H chain described in (7) and the L chain described in (8); (10) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO: 21 as CDR1, the amino acid sequence represented by SEQ ID NO: 22 as CDR2, and the amino acid sequence represented by SEQ ID NO: 23 as CDR3; (11) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO: 24 as CDR1, the amino acid sequence represented by SEQ ID NO: 25 as CDR2, and the amino acid sequence represented by SEQ ID NO: 26 as CDR3; (12) an antibody comprising the H chain described in (10) and the L chain described in (11); (13) the antibody described in any of (1) to (12) which is a chimeric antibody; (14) the antibody described in any of (1) to (12) which is a humanized antibody; (15) the antibody described in (1) or (3), comprising the amino acid sequence represented by SEQ ID NO: 28; (16) the antibody described in (2) or (3), comprising the amino acid sequence represented by SEQ ID NO: 30; (17) the antibody described in (4) or (6), comprising the amino acid sequence represented by SEQ ID NO: 32; (18) the antibody described in (5) or (6), comprising the amino acid sequence represented by SEQ ID NO: 34; (19) the antibody described in (7) or (9), comprising the amino acid sequence represented by SEQ ID NO: 36; (20) the antibody described in (8) or (9), comprising the amino acid sequence represented by SEQ ID NO: 38; (21) the antibody described in (10) or (12), comprising the amino acid sequence represented by SEQ ID NO: 40; (22) the antibody described in (11) or (12), comprising the amino acid sequence represented by SEQ ID NO: 42; (23) the antibody described in any of (15) to (22) which is a chimeric antibody; (24) an antibody that has an amino acid sequence of an antibody described in any of (1) to (23) with a substitution, deletion, addition, and/or insertion of one or more amino acid(s) and has an activity equivalent to or a binding activity equivalent to that of the antibody; (25) an antibody capable of binding to an epitope to which a second antibody binds, wherein the second antibody is the antibody described in any of (1) to (23); and (26) an antibody capable of inhibiting the binding of a second antibody to an ITM2A protein fragment consisting of amino acids 75 to 227 in the amino acid sequence represented by SEQ ID NO: 1, wherein the second antibody is the antibody described in any of (1) to (23).

Metadata:
- Claim Count in Document: 20.0
- Percentile: 86.0
- Lexical Diversity: 1.81967
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14173424', '12742892', '14008447', '12444916', '13138014']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7597356887270963
- 35 USC 102 Novelty (BERT): 0.5372639229335944
- Combined Prediction Score: 0.7374885121477461
- Mean Citation Score: 369.773784
- Max Citation Score: 386.27008
- Similarity Product: 304.5750904673767

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test